anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The role of Vascular risk factors (VRFs) in the progression of Alzheimer's Disease (AD) and cognitive decline remains to be elucidated, with previous studies resulting in conflicting findings. The possible impact of age-specific mechanisms of resilience/vulnerability is an under addressed issue. We evaluated the association of VRFs with markers of amyloid deposition, neurodegeneration, and blood-brain-barrier (BBB) permeability (Albumin quotient, Qalb), stratifying patients into early-onset (< 65, EOAD), classic late-onset (65-75, cLOAD) and very late-onset (> 75, vLOAD), to evaluate the moderating effect of age of onset. Moreover, we explored the effects of VRFs on cognitive decline at one year follow-up (ΔMMSE).
METHODS: For 368 patients with biologically confirmed AD, we computed eight risk factors in a composite measure of cumulative vascular risk (vascular score, VS). Stratifying patients according to age of onset, we regressed VS and main individual VRFs on p-tau/Aβ42, t-tau and Qalb, and used bootstrapped mediation analysis to test direct and indirect associations of VS with t-tau, using Qalb as mediator. In a subset of 105 patients, we performed multivariate backward regressions to assess the effects of sex, APOE, Qalb, VS, p-tau/Aβ42 and t-tau on ΔMMSE.
RESULTS: VS was positively associated with CSF t-tau in more vulnerable groups burdened by more aggressive disease progression (EOAD: β = 0.256, p = 0.019) or aging (vLOAD: β = 0.007, p < 0.001). Conversely, in patients with classic age of onset VS was associated with higher BBB permeability (cLOAD: β = 0.173, p = 0.015), which simultaneously causes the decrease of CSF t-tau, as a possible resilience response. Cognitive decline was not associated with VS in any of the subgroups. Instead, it was affected by both higher CSF t-tau and increased Qalb values in those with very early or very late onset (EOAD and vLOAD), but by Qalb alone in patients with classic age of onset, where CSF t-tau levels might be buffered by BBB permeability.
CONCLUSIONS: Our results show that age of onset weighs on the heterogeneous effects played by VRFs in AD, which do not seem to have direct impact on cognitive decline. These findings stress the importance of a tailored patient-centered approach to the application of vascular prevention strategies in AD.
Doxycycline hyclate delayed-release tablets USP, 75 mg are white to off-white, oval-shaped, uncoated single-score tablets with yellow speckles debossed with "70│8" on one face and plain on the other. Each tablet contains specially coated pellets of doxycycline hyclate equivalent to 75 mg of doxycycline.

Doxycycline hyclate delayed-release tablets USP, 100 mg are white to off-white, oval-shaped, uncoated single-score tablets with yellow speckles debossed with "70│9" on one face and plain on the other. Each tablet contains specially coated pellets of doxycycline hyclate equivalent to 100 mg of doxycycline.

Doxycycline hyclate delayed-release tablets USP, 150 mg are white to off-white, capsule-shaped, uncoated dual-score tablets with yellow speckles debossed with "7│1│0" on one face and dual-score on the other. Each tablet contains specially coated pellets of doxycycline hyclate equivalent to 150 mg of doxycycline.
1. A vaccine for treating prostate inflammation and benign prostate hyperplasias (stages I and II) comprising: - Lactobacillus strains in inactivated form used in vaccines Gynevac(RTM), Gyantren(RTM) and SolcoTrichovac(RTM) in an inactivated form, and - carriers and/or excipients commonly used in vaccine preparations. 2. Use of Lactobacillus strains used in the above-said in vaccines Gynevac(RTM), Gyantren(RTM) and SolcoTrichovac(RTM) in an inactivated form for treating patients suffering from prostate inflammation and benign prostate hyperplasias (stages I and II). 3. The use of claim 2 for producing vaccines capable of treating prostate inflammations. 4. The use of claim 3 for producing vaccines capable of treating benign prostate hyperplasias (stages I and II). 5. Use of Lactobacillus strains used in the above-said in vaccines Gynevac(RTM), Gyantren(RTM) and SolcoTrichovac(RTM) in an inactivated form for treating patients suffering from prostate inflammation and benign prostate hyperplasias (stages I and II). 6. A method of treating patients suffering from prostate inflammation and benign prostate hyperplasias (stages I and II) comprising administering intramuscularly an effective dose of a suspension of Lactobacillus strains used in the above-said in vaccines Gynevac(RTM), Gyantren(RTM) and SolcoTrichovac(RTM) in an inactivated to a patient in need of such treatment.
The purpose of this experimental group is to evaluate the influence of spousal involvement when receiving informational counseling. In this manner, both patients and spouses are presented with the same information regarding hearing loss and hearing aids. Couples in this experimental group will be given the same information that the patients in the first group were given. At the second visit, couples in this group will review this information together with a member of the research team for approximately 30 minutes.
In a systematic review study, it was determined that it was appropriate to practice laughter yoga for at least 4 weeks. Therefore, the laughter yoga program; It was planned as a face-to-face group session, for four (4) weeks, twice a week, for a total of eight (8) sessions and 20-25 minutes.
The prevalence of obesity-induced asthma increases in women after menopause. We hypothesized that the increase in obese asthma in middle-aged women results from estrogen loss. In particular, we focused on the acute action of estrogen through the G protein-coupled estrogen receptor 1 (GPER), previously known as GPR30. We investigated whether GPER activation ameliorates obesity-induced asthma with a high-fat diet (HFD) using G-1, the GPER agonist, and G-36, the GPER antagonist. Administration of G-1 (0.5 mg/kg) suppressed HFD-induced airway hypersensitivity (AHR), and increased immune cell infiltration, whereas G-36 co-treatment blocked it. Histological analysis showed that G-1 treatment inhibited HFD-induced inflammation, fibrosis, and mucus hypersecretion in a GPER-dependent manner. G-1 inhibited the HFD-induced rise in the mRNA levels of pro-inflammatory cytokines in the gonadal white adipose tissue and lungs, whereas G-36 co-treatment reversed this effect. G-1 increased anti-inflammatory M2 macrophages and inhibited the HFD-induced rise in pro-inflammatory M1 macrophages in the lungs. In addition, G-1 treatment reversed the HFD-induced increase in leptin expression and decrease in adiponectin expression in the lungs and gonadal white adipose tissue. The results suggest that activation of GPER could be a therapeutic option for obesity-induced asthma.
PROBLEM TO BE SOLVED: To obtain a new polynucleotide useful for screening of antibacterial compounds and for, e.g. treatment or diagnosis of a chlamydia trachomatis infection, and being much the same as a nucleic acid encoding a ratC polypeptide comprising a specific amino acid sequence. SOLUTION: This polynucleotide is a new isolated ratC polynucleotide which comprises e.g. a polynucleotide having at least 70% of the sameness as a polynucleotide encoding a polypeptide comprising the amino acid sequence of the formula or anther polynucleotide having at least 70% of the sameness as anther polynucleotide encoding the same mature polypeptide as one expressed by a ratC gene contained in a chlamydia trachomatis strain, and is useful for screening of antibacterial compounds and for, e.g. treatment or diagnosis of a chlamydia trachomatis infection. The polynucleotide is obtained by probing a typical library of a clone of a chromosome DNA of chlamydia trachomatis by using a partial sequence-derived labeled oligonucleotide.
Participants do not receive the intervention yet. They have to wait 3 months before they start with the intervention. They will fill out questionnaires at baseline, 3, 6 and 9 months.
Articular cartilage lesions in the ankle can cause significant pain and loss of function for young to middle age adults. There are several treatment options for symptomatic articular cartilage injuries depending on a patient's age, symptoms and duration of complaints in addition to the size and condition of the lesion. DeNovo NT Natural Tissue Graft is comprised of fresh particulated juvenile cartilage pieces that are secured inside articular cartilage lesions using fibrin adhesive. DeNovo NT Graft was developed due to the current need for expanded treatment options for the treatment of cartilage lesions, especially large lesions.

This post-market, multicenter, longitudinal data collection study was established to collect clinical outcomes of subjects implanted with DeNovo NT Graft. Data may be obtained either retrospectively or prospectively from patients implanted or to be implanted with DeNovo NT Graft for the treatment of lesion in the ankle. Data to be collected include details of the operative procedure as well as subject pain, function, activity levels, and healthcare resource use through a five year post-operative follow-up period.
Magnesium Sulfate in 5% Dextrose Injection is contraindicated in patients with known myasthenia gravis. 

Use of magnesium sulfate in patients with underlying myasthenia gravis can precipitate a myasthenic crisis. Myasthenic crisis is a life-threatening condition characterized by neuromuscular respiratory failure. Symptoms of myasthenic crisis may include difficulty swallowing, ptosis, facial droop, weakness and/or difficulty breathing that may require intubation. 

If myasthenic crisis is suspected, discontinue use of Magnesium Sulfate in 5% Dextrose Injection immediately. Secure the patient’s airway. Consider intensive care unit admission and elective intubation, if respiratory failure is anticipated. Once the airway is secure, confirm the diagnosis. Therapies include plasmapheresis and plasma exchange or intravenous immunoglobulin (IVIG) and immunomodulating therapy in addition to high-dose glucocorticoids.
Gait impairment remain one of the main problem for most of chronic hemiplegic stroke patients. After the 6 first months, stroke patients are classically described with moderate or no improvement for motor skills. However, physiothertapy is very often delivered to try to increase motor performance. Here, we want to compare the effectiveness of a flexor and extensor paretic knee muscular strengthening program with conventional physiotherapy delivered by the local physiotherapist of the patient, in a very ecological way. Patients will be randomly affected to one group with the same amount of physiotherapy (at least 3 times weekly for 6 weeks). Assessment will be done blindly by another physiotherapist, before, after the 6-week treatment and 6 weeks later to evaluate immediate and remaining benefits of each treatment.
The current study aimed to investigate the effectiveness and safety of the ITBS protocol, which is applied to the mPFC and ACC for 5 sessions per day with a double-cone coil in treatment-resistant OCD patients. This study evaluated (I) the effectiveness of Itbs (50 Hz) stimulation of the mPFC and ACC with a double-cone coil and (II) the effectiveness of administering this protocol over 2 weeks rather than six weeks as approved by the FDA. Participants will be randomized into two parallel groups in a double-blind manner. In one group, ITBS (50 Hz) dTMS will be applied to mPFC and ACC, and in the other group, sham tms will be applied to the same regions. The application consists of a total of 50 sessions, 5 times a day. This application will last for a total of 10 days excluding weekends.
A commercial TIVA(Total Intravenous Anesthesia and Volatile Anesthesia ) pump was used for target-controlled infusion (TCI) of remifentanil and propofol. In the volatile group, anesthesia was induced with an intravenous bolus of propofol 1.5-2 mg/kg and TCI of remifentanil (effect-site concentration \[Ce\] of 4.0 ng/ml). In the TIVA group, anesthesia was induced with TCI of propofol (Ce of 4.0-4.5 μg/ml) and remifentanil (Ce of 4.0 ng/ml). In the volatile group, anesthesia was maintained with sevoflurane (0.8-1 age-adjusted minimum alveolar concentration \[MAC\]) and TCI of remifentanil, while in the TIVA group, anesthesia was maintained with TCI of propofol and remifentanil. Anesthesia depth was adjusted to maintain a PSI(Patient State Index) of 25-50. Endotracheal intubation was performed after administration of intravenous rocuronium 1.2 mg/kg and neuromuscular blockade depth was maintained to a target of train-of-four of 0-2 with infusion of rocuronium during pneumoperitoneum.
PURPOSE:To use a safe compound, iron chlorophyllin, for preventing or treating the disorders of human bodies caused by active oxygen which is considered to cause the various disorders of the human bodies such as cancer, cardiac infarction and diabete and the deterioration of cosmetics. CONSTITUTION:A agent for preventing and treating the disorders of human bodies caused by active oxygen, containing iron chlorophyllin as an active ingredient. The iron chlorophyllin is obtained by removing magnesium from chlorophyllin with an acid, saponifying the produced pheophytin with an alkali, and subsequently compounding the produced phytochlorin with iron. The agent is used for preventing and treating disorders, e.g. aging, congenital abnormal diseases, asthma, sepsis, angiopathy, arterial sclerosis, nephritis, cataract, skin diseases such as psoriasis, cancer, cardiac infarction, diabete, rheumatism, cerebral edema, chronic pulmonary emphysema, various ischemia and autoimmunity. The deterioration of the qualities of fats, oils, etc., in foods or cosmetics is prevented. The agent is generally preferably employed in an amount of approximately <=5g/kg.
Increases in Blood Pressure in Adults

Mirabegron can increase blood pressure. Periodic blood pressure determinations are recommended, especially in hypertensive patients. Mirabegron is not recommended for use in patients with severe uncontrolled hypertension (defined as systolic blood pressure greater than or equal to 180 mm Hg and/or diastolic blood pressure greater than or equal to 110 mm Hg) [see Clinical Pharmacology (12.2)].

In two, randomized, placebo-controlled, healthy adult volunteer studies, mirabegron was associated with dose-related increases in supine blood pressure. In these studies, at the maximum recommended dose of 50 mg, the mean maximum increase in systolic/diastolic blood pressure was approximately 3.5/1.5 mm Hg greater than placebo.

In contrast, in adult OAB patients in clinical trials, mirabegron, taken as monotherapy, the mean increase in systolic and diastolic blood pressure at the maximum recommended mirabegron dose of 50 mg was approximately 0.5 to 1 mm Hg greater than placebo. Worsening of pre-existing hypertension was reported infrequently in patients taking mirabegron. 

Increases in Blood Pressure in Pediatric Patients 3 Years and Older

Mirabegron can increase blood pressure in pediatric patients. Blood pressure increases may be larger in children (3 to less than 12 years of age) than in adolescents (12 to less than 18 years of age). Periodic blood pressure determinations are recommended. Mirabegron is not recommended for use in pediatric patients with severe uncontrolled hypertension, defined as a systolic and/or diastolic blood pressure above the 99th percentile plus 5 mm Hg for age, sex, and stature using appropriate reference values [see Adverse Reactions (6.1)].
Diabetic retinopathy (DR) is the leading cause of blindness in type 1 Diabetes Mellitus (DM) patients, as a consequence of impaired blood flow in the retina. Optical coherence tomography angiography (OCT-A) is a newly developed, non-invasive, retinal imaging technique that allows detection of perfused and non perfused areas of the retina without the injection of dye. This OCT-based method permits adequate delineation of the perifoveal vascular network, and allows objective identification of microvascular changes, such as capillary dilation or presence of microaneurisms. It is also capable to detect paramacular areas of capillary non perfusion and/or enlargement of the foveal avascular zone (FAZ), representing an excellent tool for assessment of diabetic retinopathy.

Given that all these features are commonly seen in diabetic patients, the relationship of these microvascular changes with systemic factors such as metabolic control or duration of the disease still need to be elucidated. Interestingly, further studies are required to investigate whether these changes reflect those occurring elsewhere in the body affected by diabetic microvascular disease, as the kidneys or the brain. If these relationships were demonstrated, early detection of these microvascular changes could lead to modifications in the pharmacological management of diabetic patients, as a way to reduce the risk of future complications in both the eye and other organs. The aim of this study is to evaluate the role of OCT-A in the evaluation of the perifoveal vascular network in type 1 diabetic patients, and to investigate the relationship between these OCT-A-derived parameters and demographic and clinical factors, as metabolic control and duration of the disease.
The present invention makes use of Chinese herbal medicine such as euphorbia humifusa 15g, root bark of Chinese wolfberry 15g, south adenophora verticillata 12g, dwarf lilyturf 10g, gypsum 30g, rhizoma anemarrhenae 10g, root of rehmannia 15g, dead silkworms 10g, dried indigo vat froth 5g, oriental water plantain 30g, Sophora flavescens 15g to boil tisane, tea and health-care drinks. Or  the above Chinese medicine configuration are used to make the pill, the pellet, the injection, the medicinal powder, the oral, the aerosol, the oil emulsion, the sponginum, and the capsule. The present invention has new application of treating diabetes. The present invention mainly treats diabetes, with nourishing yin, clearing heat and discharging fire. The present invention is suitable to patients who are in non-insulin-dependent diabetes; to patients who drink a lot and always feel h-ungry; to patients who urinate a lot; to patients who are lassitude and weakness; to patients who are thinner day after day; to patients who are with red tongue and yellow coating; to patients who are with thin pulse. The phragmites communis, the root of trichosanthes kirilowii and the dendrobium monile are added for patients who are with diabetes involving the upper-jiao. The Chinese goldthread rhizome and the jade bamboo are added for patients who are with diabetes involving the middle-jiao. The fox-glove, the mountain cornus, the Huai Chinese yam and the hyacinth bean are used for patients who are with diabetes involving the lower-jiao. The peach kernel, the safflower, the clever arrow feather, the herbaceous peony and the salvia miltiorrhiza are added for patients who are with the blood stasis sickness.
Intensive monitoring strategy of discharging from the Emergency Department with an external 30 day cardiac monitoring system. A negative 30 day external monitor report will be followed by an implantable cardiac monitor.
PURPOSE:To provide a new substance having an antitumor property or a tumor cell multiplication-inhibiting action and capable of being obtained from a food raw material. CONSTITUTION:An antitumor substance having a tumor cell multiplication- inhibiting activity, capable of being obtained by the water extraction of the fruit body of Armillaria matsutake, and having the following physicochemical properties (1)-(6). (1) The substance is precipitated by heat and its activity is lowered. (2) The substance is salted out with ammonium sulfate. (3) The activity of the substance is lowered by a protease treatment. (4) The activity of the substance is not affected by glycosylase. (5) The maximum absorption is recognized at the wavelength of approximately 275nm in the UV ray absorption spectrum. (6) The estimated mol.wt. of the substance by a gel filtration method is the same as that of thyroglobulin or higher. A method for producing the antitumor substance is characterized by extracting the fruit body of Tricholoma with water and subsequently removing fractions up to the mol.wt. of at least 3500 from the water extract. The antitumor can be used as an antitumor agent.
Participants will receive the recommended Phase 2 JNJ-42756493 dose determined in Part 1 as Intermitting dosing regimen (28 days, 7 days on and 7 days off). Participants who are tolerating study drug treatment and achieve clinical responses or stable disease will continue to receive study drug at the same dose until disease progression, unacceptable toxicity, or withdrawal of consent.
This invention relates to a standard component 99mTC elution generator useful for medical purposes and consisting of prefabricated component parts. The main generator column of the device may be used both as an irradiation container and an elution container, enabling the user to supply activated or nonactivated parts. The main generator column made from by neutrns little activable materials serves first as reactor irradiation ampoule and after having been activated in the reactor by neutrons and after a simple adjustment serves directly as the generator column. It is filled with water insoluable molybdates or polymolybdates (with the molybdenum content in the range 10-40%), easily releasing 99mTc generated by radioactive decay of the mother 99Mo formed in it by neutron activation. This column filling serves originally as target material for reactor irradiations and afterwards it is directly used as the generator elution matrix. Accordingly, all components of the generator can be produced in a "ready-to-use" form and supplied as inactive material. When nonactivated parts are used, activation is performed on-site by a local reactor. The use of nonactivated parts is advantageous because they are more easily and more safely manufactured and transported. The invention further provides for efficient generation of 99mTC radionuclides from medium neutron flux irradiation of molybdenum in a natural isotopic mixture.
Abstract The present disclosure provides compositions and methods for on-going bowel care for persons with chronic intestinal pseudo-obstruction. The compositions and methods can be administered in a non-clinical setting. The compositions comprise acetylcholinesterase inhibitors for stimulating motility of the bowel in combination with anti- cholinergic agents to counteract the potentially dangerous cardiac side effects of the acetylcholinesterase inhibitor. In some examples, the acetylcholinesterase inhibitor, neostigmine, and the anti-cholinergic agent, glycopyrrolate, are combined in a pharmaceutical composition. Certain examples also provide the frequency and duration of administration of the disclosed drug combinations. Date Recue/Date Received 2020-12-30
Congestive heart failure and sudden cardiac death are associated complications of aortic stenosis. Currently, the indications for valvular replacement are based on the valvular severity evaluated by echocardiography and the presence of symptoms. There is some evidence to suggest the presence of myocardial fibrosis is associated with a poor outcome in patients with aortic stenosis. The aim of this prospective study is to investigate the prognostic implications of myocardial fibrosis in patients with aortic stenosis. The presence of myocardial fibrosis will be identified by delayed enhancement with the cardiac magnetic resonance imaging at 3T. We will also be evaluating the application of T1 mapping techniques to detect diffuse myocardial fibrosis.